Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients.
Publication Title
JCI Insight
Document Type
Article
Publication Date
1-23-2025
Keywords
Humans; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Receptors, Antigen, T-Cell; Animals; Mice; CD8-Positive T-Lymphocytes; CD4-Positive T-Lymphocytes; HLA-A11 Antigen; Mutation; Cell Line, Tumor; Xenograft Model Antitumor Assays; Interferon-gamma; Female; Cancer immunotherapy; Immunology; Oncology; T cell receptor; T cells; oregon; portland; chiles
Abstract
T cells targeting a KRAS mutation can induce durable tumor regression in some patients with metastatic epithelial cancer. It is unknown whether T cells targeting mutant KRAS that are capable of killing tumor cells can be identified from peripheral blood of patients with pancreatic cancer. We developed an in vitro stimulation approach and identified HLA-A*11:01-restricted KRAS G12V-reactive CD8+ T cells and HLA-DRB1*15:01-restricted KRAS G12V-reactive CD4+ T cells from peripheral blood of 2 out of 6 HLA-A*11:01-positive patients with pancreatic cancer whose tumors expressed KRAS G12V. The HLA-A*11:01-restricted KRAS G12V-reactive T cell receptor (TCR) was isolated and validated to specifically recognize the KRAS G12V8-16 neoepitope. While T cells engineered to express this TCR specifically recognized all 5 tested human HLA-A*11:01+ and KRAS G12V+ pancreatic cancer organoids, the recognition was often modest, and tumor cell killing was observed in only 2 out of 5 organoids. IFN-γ priming of the organoids enhanced the recognition and killing by the TCR-engineered T cells. The TCR-engineered T cells could significantly slow the growth of an established organoid-derived xenograft in immunodeficient mice. Our data suggest that this TCR has potential for use in TCR-gene therapy, but additional strategies that enhance tumor recognition by the TCR-engineered T cells likely will be required to increase clinical activity.
Area of Special Interest
Cancer
Specialty/Research Institute
Oncology
DOI
10.1172/jci.insight.181873
